Awakn Life Sciences - Revolutionary Treatments For Addiction

Revolutionary treatments
for addiction

Revolutionary treatments
for addiction

About Awakn

Awakn Life Sciences is a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder

OBJECTIVE:
To provide breakthrough therapeutics to addiction sufferers

STRATEGY:
To commercialize our R&D pipeline across multiple channels

Drugs and therapies used in combination

Addiction is one of the world’s biggest unmet medical needs. Substance and behavioural addictions affect over 1.3¹ billion people worldwide. Yet all current treatments have high failure rates.

Awakn is developing a better solution to treat addiction: psychedelic therapeutics – drugs and therapies used in combination. We are a biotech company researching, developing and commercializing these therapeutics.

Through clinical trials, our team has shown that this approach has the potential to be more effective than any addiction treatment currently available. We now aspire to become the market leader in effective addiction treatment, meeting a vast global need that is failed by current approaches.

Investment Highlights

Significant market opportunity and proven science that can provide effective therapy to patients in desperate need.

Significant Addressable Market

285 million people globally are affected by AUD
Global AUD treatment market is valued at US $25bn per annum
Existing AUD treatments lack efficacy, with 75% relapse rates
~20% of global adult population affected by addictions

Deep Pipeline With Proven Efficacy

Lead program progressing to phase III. Phase II results were 3.4 times more effective than the current standard of care
Partnership with Catalent to develop MDMA on Catalent’s Zydis® Oral Dissolving Tablet (ODT)
Appropriate IP strategies in place
Deep pipeline developed with relatively low capital investment

Commercialization

Currently commercializing in 4 territories across 2 revenue streams:
- 24% revenue growth Q1 ‘22
- 34% revenue growth Q2 ‘22
- 27% revenue growth Q3 ‘22
Future value realization opportunities through sale or licensing of R&D assets

Highly Experienced Team

Global leading addiction experts
Track record of successful research, development and commercialization
Supportive ‘blue chip’ investor base

FIND OUT MORE »

Our Therapy and Drug Development Pipeline

Addiction: The other pandemic

Between 15-20% of adults suffer from substance addictions¹, and many others from behavioural addictions.

Yet available treatments are poor. Just 16% of Alcohol Use Disorder sufferers seek treatment, and up to 75%² of those people relapse within 12 months. Behavioural addictions are so poorly served there is no good data available on either treatment or success rates.

Despite these high failure rates, $17bn³ per year (and rising) is spent by on private addiction treatment. The individuals footing this bill have a right to expect more.

Our unique evidence-based approach

Awakn is developing a revolutionary new approach for treating substance and behavioural addictions.

Based on new research, Awakn’s drugs uniquely target the brain circuits that drive addiction, through multiple receptors rather than the single drug receptors targeted by existing treatments. These circuits control the behavioural drivers of addiction. By focusing on circuit mechanisms rather than isolated receptors, our treatments have the potential to be effective in the treatment of both substance and behavioural addictions.

This brain circuit-disruption allows the individual to engage with Awakn’s psychotherapeutic process in unique ways that enable clients to escape repetitive addictive behaviours and thoughts; and make long lasting positive changes.

Awakn’s team has successfully conducted the world’s only clinical trials of ketamine and MDMA in a therapeutic setting as treatments for alcohol use disorder. We are now conducting trials for other addictions, including gambling, Binge Eating Disorder, Internet Gaming Disorder and Compulsive Sexual Bahavior and building a pipeline of patentable psychedelic therapeutics that will create even more effective medicines in future.

Together, this gives us a world-beating proposition for tackling addiction.

LEARN MORE ABOUT OUR WORK »

Backed by the world’s leading experts